With antibodies produced from mouse and human components, this biotech is advancing drug research.
Will the biotech need to find a suitor after the halting of a once-promising development program?
Shares of a 3% dividend yield, solid blue-chip drug company are valuable in shaky economic times.
After a huge fraud settlement, the drug company has new management and a promising future.
In a unanimous vote, government advisors said the benefits of a treatment for multiple myeloma outweigh the risks.
With reliable earnings and dividends, this stalwart is a AAA-rated play in health care.
The longtime partners may finally tie the knot.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
Despite paying record fines and charging high fees, financial institutions are no longer hated.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
More than half of online shoppers say they've purchased from sites whose security seemed questionable, and most said they would provide personal data not normally needed for a transaction.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.